1286738-63-3

Upstream product

• 1232030-40-8 6-bromo-8-ethyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 100-00-5 4-chlorobenzonitrile 
• 109-01-3 1-methyl-piperazine 
• 16155-03-6 1-methyl-4-(4-nitrophenyl)piperazine 
• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 211244-81-4 2-methanesulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 352328-87-1 6-bromo-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1232030-55-5 6-bromo-8-ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1286738-62-2 6-bromo-8-ethyl-2-methanesulfinyl-8H-pyrido[2,3-d]pyrimidin-7-one 

Downstream Products

• 1286738-64-4 3-chloro-4-{8-ethyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl}-benzoic acid hydrazide 
• 1286738-61-1 6-(2-chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-8-ethyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one 

Relevant academic research and scientific papers

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

PAK INHIBITORS FOR THE TREATMENT OF CANCER

Provided herein are methods of utilizing PAK inhibitors for the treatment of cancer. Further provided herein are compounds and formulations utilized for the treatment of cancer.